PPBT vs. LIPO, NEUP, ALLR, ATHA, TXMD, NERV, AYTU, EQ, BCDA, and PHIO
Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Lipella Pharmaceuticals (LIPO), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Allarity Therapeutics (ALLR), Athira Pharma (ATHA), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Aytu BioPharma (AYTU), Equillium (EQ), BioCardia (BCDA), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry.
Purple Biotech vs. Its Competitors
Lipella Pharmaceuticals (NASDAQ:LIPO) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Purple Biotech received 16 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 94.44% of users gave Purple Biotech an outperform vote.
Purple Biotech has a consensus target price of $33.00, suggesting a potential upside of 1,316.31%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Lipella Pharmaceuticals.
Purple Biotech has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Purple Biotech's return on equity of -17.84% beat Lipella Pharmaceuticals' return on equity.
In the previous week, Lipella Pharmaceuticals had 2 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Lipella Pharmaceuticals and 1 mentions for Purple Biotech. Lipella Pharmaceuticals' average media sentiment score of 0.50 beat Purple Biotech's score of 0.00 indicating that Lipella Pharmaceuticals is being referred to more favorably in the media.
Lipella Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
Lipella Pharmaceuticals has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Purple Biotech beats Lipella Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Purple Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Purple Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:PPBT) was last updated on 6/21/2025 by MarketBeat.com Staff
